Global Obesity Management Industry Overview | By Major Market Players Heartland Pfizer Inc. (US), straZeneca (UK), VIVUS Inc., Arena Pharmaceuticals Inc., Novo Nordisk A/S, Allergan Plc, Medtronic, Cousin Biotech

March 2019, Pune, India (News) – Global Obesity Management Industry was valued at USD 5.7 Billion in the year 2019. Global Obesity Management Industry is further estimated to grow at a CAGR of 8.5% from 2019 to reach USD 7.92 Billion by the year 2025. Obesity management Industry is developing respectably. Changing way of life and unhealthy eating habit are prompting the issue of Obesity. The number of inhabitants in stout individuals are expanding all around. Stoutness prompts different sicknesses, for example, diabetes, hypertension, heart maladies and numerous others. Medications producers putting their cash in R&D to create successful enemy of corpulence drugs. Prior weight was considered as issue of high salary nations however at this point it’s moving towards low-center pay nations. Healthcare solution suppliers are growing new and imaginative answers for medicinal services part. Clinics likewise giving diverse medical procedure alternatives as indicated by medicinal history and state of the patient.

Ask For Free Sample at https://www.globalreportsstore.com/request-sample/11707

In 2016, World Health Organization (WHO) expressed that around 41 million kids under who age under 5 were evaluated to be overweight or large. Besides, it was assessed that around 600 million grown-ups were obese around the same time.

Moreover, alongside business accessibility of answers for weight the board, mechanical progressions presented by the vertical players and strong activities attempted by the governments, make more mindfulness as to Obesity and its effect on health. This is further driving the development of the Obesity treatment advertise.

Major Industry players in Obesity Management Industry are Heartland Pfizer Inc. (US), straZeneca (UK), VIVUS Inc., Arena Pharmaceuticals Inc., Novo Nordisk A/S, Allergan Plc, Medtronic, Cousin Biotech, EnteroMedics Inc., and USGI Medical Inc., Merck Sharp & Dohme Corp., Ethicon Inc. (USA), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc. (UK), AstraZeneca (UK), Herbalife Ltd. (U.S.), Apollo Endosurgery (U.S.), Ethicon Inc. (U.S.)

Obesity Management Industry Segmentation:

Obesity Management Industry Overview, By Type

  • Combination Drugs
  • Appetite Suppressants
  • Malabsorption
  • Satiety

Obesity Management Industry Overview, By Surgery & Devices

  • Adjusting Gastric Banding
  • Roux-en-Y Gastric Bypass
  • Sleeve Gastrectomy
  • Biliopancreatic Diversion with Duodenal Switch
  • Endoscopic Procedures

Directly Get Corporate Copy of this report at 2990 USD at https://www.globalreportsstore.com/checkout/11707

Table of Contents

1. Introduction

1.1 Industry Vision

1.2 Limitations

1.3 Stakeholders

2. Research Methodology

2.1. Research Process

2.1.1. Secondary Research

2.1.2. Primary Research

2.2. Industry Size Estimation

2.2.1. Bottoms-Up Approach

2.2.2. Top-Down Approach

2.2.3. Annual Turnover Process

2.3. Data Triangulation

2.4. Research Assumptions

2.4.1. Assumption

3. Executive Summary

4. Industry Overview

4.1. Introduction

4.2. Strength

4.3. Weakness

4.4. Opportunities

4.5. Threats

5. Industry Trends

5.1. Introduction

5.2. Porter’s Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Threat of Substitutes

5.2.3. Bargaining Power of Buyers

5.2.4. Bargaining Power of Suppliers

5.2.5. Intensity of Competitive Rivalry

6. Obesity Management Industry, By Type

6.1. Combination Drugs

6.2. Appetite Suppressants

6.3. Malabsorption

6.4. Satiety

7. Obesity Management Industry, By Surgery & Devices

7.1. Adjusting Gastric Banding

7.2. Roux-en-Y Gastric Bypass

7.3. Sleeve Gastrectomy

7.4. Biliopancreatic Diversion with Duodenal Switch

7.5. Endoscopic Procedures

8. Geographical Analysis

8.1. Introduction

8.2. North America

8.2.1. U.S.

8.2.2. Canada

8.2.3. Mexico

8.3. Europe

8.3.1. Germany

8.3.2. France

8.3.3. U.K.

8.3.4. RoE

8.4. Asia Pacific

8.4.1. China

8.4.2. Japan

8.4.3. India

8.4.4. RoAPAC

8.5. RoW

8.5.1. Latin America

8.5.1.1. Brazil

8.5.1.2. Argentina

8.5.1.3. Rest of Latin America

8.5.2. Middle East and Africa

9. Company Profiles

9.1 straZeneca (UK)

9.1.1 Company Overview

9.1.2 Financial Overview

9.1.3 Product Overview

9.1.4 Current Development

9.2. Heartland Pfizer Inc. (US)

9.3. VIVUS Inc.

9.4. Arena Pharmaceuticals Inc.

9.5. Novo Nordisk A/S

9.6. Allergan Plc

9.7. Medtronic

9.8. Cousin Biotech

9.9. EnteroMedics Inc.

9.10. and USGI Medical Inc.

9.11. Merck Sharp & Dohme Corp.

9.12. Ethicon Inc. (USA)

9.13. F. Hoffmann-La Roche Ltd (Switzerland)

9.14. GlaxoSmithKline plc. (UK)

9.15. AstraZeneca (UK)

9.16. Herbalife Ltd. (U.S.)

9.17. Apollo Endosurgery (U.S.)

9.18. Ethicon Inc. (U.S.)

10. Competitive Analysis

10.1. Introduction

10.2. Industry Positioning of Key Players

10.3 Competitive Strategies Adopted by Leading Players

11. Appendix

11.1. Questionnaire

11.2. Available Customizations

11.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

 Contact Us

Jon

Mob +91-739-102-4425

Email Sales@globalreportsstore.com

Contact Us

Jon

Mob +91-739-102-4425

Email Sales@globalreportsstore.com


Leave a Reply

Your email address will not be published. Required fields are marked *